Mainstreaming genetic testing by oncology teams

A focus on genetic testing in patients with breast and ovarian cancers

Register to the program
New user

This learning activity is for healthcare professionals only

About the program

Mainstream genetic testing in patients with cancer is performed through the patient’s own oncology team during their existing oncology appointments, with support as required from the familial cancer centre (FCC) or genetics service.1

This learning activity for healthcare professionals takes a step-by-step approach to the mainstreaming process and its role in the management of patients with ovarian and/or breast cancer. It also outlines how oncology teams can implement mainstream genetic testing in their own oncology units.

The Mainstreaming Working Party for the COSA Familial Cancer Group recommends that all members of oncology teams who engage in mainstream genetic testing should complete this training module, or a similar training programme run by their local FCC or genetics service, prior to starting mainstream genetic testing.

Program Learning Objectives:

By completing this learning activity, you will be able to:

  • Describe the process of mainstream genetic testing.
  • Outline the benefits of mainstream genetic testing for patients with ovarian and/or breast cancer, and the potential implications for their family members.
  • Understand how genetic testing results can guide treatment decisions in ovarian and/or breast cancer.
  • Identify patients eligible for testing, oversee the consenting process, order the genetic test, and deliver the result to patients.
  • Confidently implement mainstream genetic testing in your oncology unit.

This activity has been developed by a Steering Committee from the Mainstreaming Working Group for the Clinical Oncology Society of Australia (COSA) Familial Cancer Special Interest Group. The module has been supported by AstraZeneca through an independent third party agreement between the sponsor and COSA. Medical writing, digital development and in-kind support has been provided by The Med Collective and JHL Digital.

1.Rahman N. Clin Med 2014;14:436-439.